Invivyd, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Invivyd, Inc. (IVVD)
Company Research
Source: Yahoo! Finance
Invivyd, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Execution and Clinical Rationale Management attributes the strategic shift toward monoclonal antibody (mAb) prophylaxis to the diminishing efficacy of serial COVID-19 vaccine boosting against immune-evasive Omicron variants. The Declaration study for VYD2311 reached target enrollment of approximately 1,770 subjects, utilizing a triple-blind design to assess symptomatic COVID-19 reduction versus placebo. Operational progress is supported by an Independent Data Monitoring Committee (IDMC) review which relaxed enrollment criteria for pregnant/breastfeeding women and removed several mid-study safety visits. The company is positioning its mAb platform as a 'vaccine-alternative' strategy, arguing that direct antibody administration avoids the potential risks and short duration associated with repeated spike protein exposure. Commercial growth for PEMGARDA, with a 31% sequential revenue increase, is being used to estab
Show less
Read more
Impact Snapshot
Event Time:
IVVD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IVVD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IVVD alerts
High impacting Invivyd, Inc. news events
Weekly update
A roundup of the hottest topics
IVVD
News
- Invivyd Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Invivyd, Inc. (IVVD) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates [Yahoo! Finance]Yahoo! Finance
- Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer [Yahoo! Finance]Yahoo! Finance
- Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial UpdatesGlobeNewswire
IVVD
Earnings
- 3/5/26 - Miss
IVVD
Sec Filings
- 3/5/26 - Form 10-K
- 3/5/26 - Form 8-K
- 2/18/26 - Form 4
- IVVD's page on the SEC website